D. E. Shaw & Co. Inc. Increases Holdings in Twist Bioscience Co. (NASDAQ:TWST)

D. E. Shaw & Co. Inc. raised its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 1,085.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,268 shares of the company's stock after acquiring an additional 98,223 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.18% of Twist Bioscience worth $4,985,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of TWST. First Light Asset Management LLC bought a new stake in Twist Bioscience during the fourth quarter valued at about $56,984,000. Marshall Wace LLP increased its holdings in shares of Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after purchasing an additional 840,828 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after purchasing an additional 302,884 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Twist Bioscience by 63.5% in the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock worth $35,148,000 after purchasing an additional 293,751 shares during the last quarter.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 1,877 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the transaction, the chief operating officer now owns 240,783 shares in the company, valued at $7,163,294.25. The trade was a 0.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Laponis sold 936 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the transaction, the chief financial officer now owns 106,018 shares of the company's stock, valued at $3,154,035.50. This trade represents a 0.88% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,011 shares of company stock worth $951,499 over the last 90 days. Company insiders own 3.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Barclays reduced their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Trading Up 0.4%

TWST traded up $0.10 on Friday, hitting $28.26. The company had a trading volume of 781,842 shares, compared to its average volume of 976,364. The company has a market cap of $1.69 billion, a PE ratio of -8.36 and a beta of 2.54. Twist Bioscience Co. has a 12-month low of $27.12 and a 12-month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business's fifty day simple moving average is $36.71 and its 200 day simple moving average is $42.85.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Equities research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.